A Phase (ph) I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (Anti-Il23 Monoclonal Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
JOURNAL OF CLINICAL ONCOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要